Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Market Cap	25.66B
Revenue (ttm)	1.80B
Net Income (ttm)	-222.18M
Shares Out	n/a
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Average Volume	533
Open	253.80
Previous Close	250.30
Day's Range	247.48 - 253.80
52-Week Range	143.66 - 254.88
Beta	n/a
RSI	36.27
Earnings Date	Feb 20, 2025

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HD2

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD